Monday, December 23, 2024
HomeTagsTWT-203

TWT-203

Treadwell Announces Initiation of Patient Dosing in TWT-203, a Phase 1b/2 study of TTK Inhibitor, CFI-402257, in Patients with ER+/Her2- Breast cancer

Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, announced the initiation of patient dosing in TWT-203, its Phase...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics